ProKidney’s stock rockets on ‘intriguing’ news, but analyst doesn’t recommend buying

ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the biotech’s CKD and diabetes treatment.

Source: MarketWatch

Continue reading...